Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.

De Boer R, Beith J, Chirgwin J, Chua S, Colosimo M, Francis P, Green M, Pittman K, White M, Wilcken N, Zdenkowski N, Bell R.

Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:15-25. doi: 10.1111/ajco.12207. Review.

PMID:
24797446
2.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
3.

Current and future anti-HER2 therapy in breast cancer.

Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.

J BUON. 2013 Jan-Mar;18(1):4-16. Review.

PMID:
23613383
4.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
5.

Treatment of HER2-positive metastatic breast cancer following initial progression.

Mayer IA.

Clin Breast Cancer. 2009 Jun;9 Suppl 2:S50-7. doi: 10.3816/CBC.2009.s.005. Review.

6.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Review.

PMID:
23481218
7.

Issues and controversies in the treatment of HER2 positive metastatic breast cancer.

Amar S, Moreno-Aspitia A, Perez EA.

Breast Cancer Res Treat. 2008 May;109(1):1-7. Review.

PMID:
17653858
8.

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S, Pronzato P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1391-405. doi: 10.1586/era.12.107. Review.

PMID:
23072512
9.

Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.

Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R.

Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:1-14. doi: 10.1111/ajco.12206. Review.

PMID:
24797445
10.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
11.

Treatment strategy for HER2-positive breast cancer.

Mukai H.

Int J Clin Oncol. 2010 Aug;15(4):335-40. doi: 10.1007/s10147-010-0107-0. Review.

PMID:
20632056
12.
13.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1.

PMID:
20087739
14.

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.

Cancer. 2007 Sep 1;110(5):965-72.

15.

Overcoming treatment challenges in advanced breast cancer.

Harkins B, Geyer CE Jr.

Semin Oncol Nurs. 2007 Nov;23(4 Suppl 2):S10-6. doi: 10.1016/j.soncn.2007.10.003. Review.

PMID:
18054677
16.

Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS.

Clin Cancer Res. 2003 Jul;9(7):2440-6.

17.

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.

Breast Cancer Res. 2005;7(4):R436-43.

18.

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

Nielsen DL, Kümler I, Palshof JA, Andersson M.

Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Review.

PMID:
23084121
19.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

20.

Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies.

Mannocci A, De Feo E, de Waure C, Specchia ML, Gualano MR, Barone C, Ricciardi W, La Torre G.

Tumori. 2010 May-Jun;96(3):385-91. Review.

Items per page

Supplemental Content

Support Center